Corentel H

Quick links to important sections

Corentel H

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corentel H

Property Description
Active ingredient Bisoprolol Fumarate and Hydrochlorothiazide (HCTZ)
Form Oral Tablet (Film-coated)
Pharmacological class Antihypertensive Agents (Beta-blocker and Thiazide Diuretic combination)
Common use Management of Hypertension (High Blood Pressure)
Origin Synthetic Fixed-Dose Combination

What Type of Medicine is Corentel H?

Corentel H is a prescription-only, synthetic fixed-dose combination product classified generally as an antihypertensive agent. It is supplied for oral administration in the form of a tablet. This medicine is structurally equivalent to other formulations containing the same active ingredients, positioning it as a key option within the field of combination antihypertensive therapy. The fixed-dose format simplifies the therapeutic regimen compared to taking two separate tablets, a strategy clinically recognized for its role in supporting effective patient management.


Dual-Action Composition and General Purpose

The foundation of Corentel H is its dual-action composition, which includes the two active ingredients: Bisoprolol Fumarate and Hydrochlorothiazide (HCTZ). Bisoprolol is classified as a cardioselective β-blocker. Concurrently, Hydrochlorothiazide is a thiazide diuretic that functions by inhibiting sodium reabsorption in the distal renal tubules, promoting the excretion of excess water and salt. The overall purpose of this composition is to maintain stable and reduced blood pressure levels. By reducing the heart's workload and simultaneously decreasing the overall fluid volume in the circulation, the medicine effectively manages elevated pressure, which is crucial for reducing the risk of cardiovascular events associated with uncontrolled hypertension.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Corentel H?

Corentel H's safety profile, documented in official regulatory sources, describes adverse reactions classified by frequency and body system. The most Common effects (occurring in ge 1% of patients) are generally transient, particularly fatigue, dizziness, and headache, which often appear at the beginning of therapy. Other common effects include bradycardia (slow heart rate), feeling of coldness in extremities, and gastrointestinal complaints (e.g., nausea, diarrhea).

Reactions classified as Uncommon or Rare involve systems such as the nervous system (e.g., sleep disorders, syncope), skin (e.g., photosensitivity, aggravation of psoriasis), and metabolic disorders (e.g., hyperuricemia).

Serious Adverse Reactions highlighted in regulatory warnings include Acute Angle-Closure Glaucoma and the potential for Non-melanoma Skin Cancer ( NMSC), which is associated with the long-term cumulative use of the hydrochlorothiazide component. The combination product is also associated with severe electrolyte imbalances and the risk of worsening pre-existing heart failure.

Usage is formally restricted for patients with severe renal impairment or severe hepatic impairment. The regulatory label also specifies that therapy should not be abruptly discontinued, particularly in patients with existing coronary artery disease, as this carries a risk of exacerbating angina or precipitating myocardial infarction. The beta-blocker component may also mask the signs of certain conditions, such as hypoglycemia or hyperthyroidism, which is a key safety consideration defined in official documents.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Corentel H (Bisoprolol/Hydrochlorothiazide) overdose details specific consequences of over-exposure to both active components.

Overdose manifestations primarily affect the cardiovascular and metabolic systems:

  • Cardiovascular Depression: Marked bradycardia, profound hypotension, and potential acute cardiac failure or cardiogenic shock are documented outcomes related to the Bisoprolol component.
  • Systemic Imbalance: The Hydrochlorothiazide component may cause severe fluid and electrolyte imbalance, leading to dehydration, hypokalemia, and risk of acute renal failure. Other effects include bronchospasm, hypoglycemia, and CNS symptoms such as lethargy and confusion.

Immediate Regulatory Action Required

In the event of a suspected or confirmed overdose, the regulatory instruction is to seek immediate medical attention or contact emergency services immediately due to the potential for life-threatening complications. Management is described as symptomatic and supportive treatment, focused on correcting electrolyte deficits, maintaining circulatory function, and addressing bradycardia. No specific antidote is known for this fixed-dose combination. Intensive monitoring of cardiovascular status, serum electrolytes, and blood glucose is required following exposure.

Patients with pre-existing renal or hepatic impairment, or diabetes, are noted in regulatory information to be at increased risk for certain severe outcomes.

Therapeutic Uses of Corentel H

What Corentel H Treats: Main Uses and Benefits

Corentel H is a combination medication primarily indicated for the long-term management of essential hypertension (chronic high blood pressure) in adults. The fundamental purpose is to address the sustained elevation of systemic pressure readings and the underlying physiological factors that contribute to this condition. The therapy generally contributes to support for the cardiovascular system. The medicine is used to establish and maintain consistent blood pressure control when combination therapy is considered relevant.


This medication is applied across therapeutic domains involving symptoms related to systemic imbalance, specifically factors related to symptoms of increased neurological or muscular activity and symptoms related to systemic imbalance. It is commonly used to help manage chronic conditions characterized by sustained high pressure and is considered relevant when supportive symptom management is appropriate. The key therapeutic benefit may be a contribution to easing the risk of serious cardiovascular events.

“The goal is to provide supportive relief that helps patients cope more steadily with their chronic pressure management needs.”

Indication Listing: Corentel H is used for the management of essential hypertension, supporting the regulation of sustained elevated arterial pressure and helping to mitigate the associated risk of major cardiovascular events.

Quick Fact: Relief for Systemic Imbalance
This combination helps address symptom clusters that may become disruptive by supporting effective management of symptoms linked to organ-specific functional stress and symptoms related to systemic imbalance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Corentel H? – Official Regulatory Information

Eligibility for Corentel H (a combination of bisoprolol and hydrochlorothiazide) is strictly defined by government regulatory documents, focusing on absolute contraindications and mandatory restrictions.

Contraindicated Populations

This medicine must not be used in individuals with:

  • Hypersensitivity (allergy) to bisoprolol, hydrochlorothiazide, or any other sulfonamide-derived medicines.
  • Severe heart conditions, including acute, uncontrolled heart failure, cardiogenic shock, second or third-degree atrioventricular (AV) block (without a pacemaker), and severe symptomatic bradycardia.
  • Severe organ impairment, such as anuria, severe renal impairment (creatinine clearance less than 30 ml/min), or severe hepatic impairment.
  • Metabolic/Electrolyte issues like refractory hypokalaemia or metabolic acidosis.
  • Severe asthma or severe peripheral circulatory disorders.
  • Pregnancy (specifically during the second and third trimesters).

Restricted and Special-Consideration Use

Use requires special caution and monitoring in patients with diabetes mellitus (as symptoms of low blood sugar may be masked), compensated heart failure, milder renal or hepatic impairment, and a history of gout. The medication is not recommended for the paediatric population as its safety and efficacy in children have not been established in regulatory labelling.

What should I know about interactions with other medicines?

Corentel H, containing the antihypertensive agents Bisoprolol Fumarate and Hydrochlorothiazide, has officially documented interaction patterns that regulate its co-administration with several medicinal products and substances. Combination with other beta-blocking agents is strictly prohibited in regulatory labeling. Furthermore, the combination with calcium antagonists of the Verapamil or Diltiazem type, Class I antiarrhythmic drugs, and centrally acting antihypertensive drugs is generally not recommended due to risks related to cardiac function and severe rebound effects.

Pharmacodynamic interactions are defined by the additive lowering of blood pressure, noted when Corentel H is co-administered with Dihydropyridine-type calcium antagonists or alcohol. Co-administration with Digitalis glycosides increases the risk of bradycardia. The profile warns that for patients on insulin or oral antidiabetic drugs, the beta-blockade may officially mask the symptoms of hypoglycemia.

Pharmacokinetic alterations are also documented: the systemic exposure of Bisoprolol is reduced by agents like Rifampin, which increases its metabolic clearance. Conversely, Bisoprolol's half-life is officially documented as increased approximately threefold in patients with severe renal impairment ( CrCl < 40 mL/min), resulting in increased systemic exposure. A mandatory timing constraint is applied to co-administration with multivitamins with minerals, which must be separated by at least two hours to prevent decreased absorption. Food consumption is noted to not affect the absorption of Corentel H.

Mechanism of Action

How Corentel H Works: Mechanism of Action

Corentel H combines two mechanistically distinct agents, Bisoprolol and Hydrochlorothiazide, which act on both the cardiac system and fluid dynamics.


Cardiovascular Sympathetic Dampening

This mechanism centers on the Bisoprolol component, which acts as a competitive antagonist of mathbfbeta1-adrenergic receptors primarily on the heart and juxtaglomerular apparatus. By blocking the binding of stimulating catecholamines, it initiates a cascade that decreases heart rate and reduces the force of contraction (negative chronotropy and inotropy). This action directly lowers cardiac output and suppresses the release of renin.


Renal Electrolyte and Volume Regulation

This pathway is managed by Hydrochlorothiazide (HCTZ), which inhibits the mathbf Na^+/ Cl^- co-transporter in the distal convoluted tubule of the kidneys. This prevents the reabsorption of sodium and chloride, leading to increased water excretion (diuresis) and a reduction in plasma volume. This effect alters fluid homeostasis, resulting in a reduction of circulating fluid volume and systemic pressure.


Neurohormonal and Fluid Synergy

The combination employs distinct, non-overlapping mechanisms to influence multiple physiological regulators. The simultaneous modulation of cardiac output and circulating fluid volume thereby contributes to the drug's resultant physiological activity.

Dosage and Administration Information

How to Use Corentel H

Corentel H, a fixed-dose combination of Bisoprolol Fumarate and Hydrochlorothiazide (HCTZ), is administered exclusively via the oral route as a film-coated tablet. Official administration guidelines establish a standardized protocol for starting, adjusting, and discontinuing the medicine, strictly defining how it must be used for chronic conditions.


Official Dosing and Frequency

Established guidelines outline a specific once-daily schedule for Corentel H. The standard starting dose for adult patients is typically the lowest approved strength, which is one 2.5 mg/6.25 mg tablet.

Administration Principle Guideline
Dosing Frequency Once daily (typically in the morning).
Dose Titration Adjustments (increases) should occur at intervals of at least 14 days.
Maximum Labeled Dose 20 mg Bisoprolol / 12.5 mg HCTZ daily.

Administration Requirements and Protocol

The tablets should be swallowed whole with liquid and must not be chewed or crushed. Corentel H can be taken with or without food. If a dose is missed, it should be taken as soon as remembered, unless it is close to the time for the next dose, in which case the missed dose should be skipped; a double dose must not be taken.

For discontinuing therapy, the medicine must never be stopped abruptly. Standard instructions require the dosage to be tapered gradually over a period of approximately two weeks to maintain procedural safety. Regarding specific populations, no dose adjustment is generally needed for older adults or for patients with mild-to-moderate kidney impairment (creatinine clearance > 30 mL/ min), but use is not recommended for the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Corentel H

Corentel H, which contains a combination of bisoprolol fumarate and hydrochlorothiazide, was the subject of research exploring its use in essential hypertension, which is chronic high blood pressure. The research examines physiological parameters and stress indicators to provide insight into patterns observed in the body. Research contributes to the broader evidence landscape and highlights what is still uncertain regarding this combination.

Study Designs Used to Measure Blood Pressure Change

The main evidence base for this medication comes from controlled clinical studies, primarily Randomized Controlled Trials (RCTs). These studies were used to evaluate blood pressure measurements during defined time intervals. The populations examined were mainly adults with mild to moderate high blood pressure.

Research focused on measuring two main outcomes: the level of change in sitting systolic and diastolic blood pressure readings from the start of the study, and the percentage of participants who recorded blood pressure values at or below pre-defined levels. Studies also monitored other physiological parameters, such as heart rate. Research highlights changes measured during the study period, and these findings describe patterns observed in the specific populations that were studied.


Research Examining Corentel H Against Other Trial Groups

Studies explored the use of the combination pill in comparison to various trial groups. Research examined measurements when Corentel H was observed in comparison to an inactive pill, known as a placebo. Other trials were conducted that examined the combination against the individual components taken alone (bisoprolol or hydrochlorothiazide). The comparisons contributed to the broader evidence landscape regarding patterns of measurement in blood pressure.


Long-Term Studies and Follow-Up Duration

Most primary efficacy studies available for this specific fixed-dose combination were evaluated over short-term to intermediate-term follow-up durations, commonly lasting for 4 to 12 weeks, or up to six months. Therefore, there is limited information for long-term outcomes that span multiple years of continuous use. Long-term data concerning major health events (such as stroke or heart attack) are often based on the established evidence for the individual drug classes over extended periods, rather than being collected directly from multi-year trials of the fixed-dose product itself. Long-term effects are not fully established based on the primary combination research.


What is Still Uncertain About Corentel H Research

Several areas in the research landscape remain uncertain or are limited. One key limitation is that the follow-up durations were limited in many of the trials focused on efficacy, meaning insights into sustained outcomes for chronic, lifelong pressure management are still emerging. Another limitation is that the results apply only to the populations studied, and the evidence quality varies across studies when examining certain subgroups. Comparative evidence against certain alternative drug combinations is lacking. Research is ongoing to better understand these patterns, and study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Corentel H (FAQ)


Q: Are there any common foods or supplements that should not be taken with Corentel H?

Official product information details potential interactions with substances that affect heart rate or potassium levels in the body. For instance, regulatory labeling advises that mineral-containing products, such as some multivitamins, should be taken at least two hours apart from Corentel H to prevent reduced absorption. Reviewing all existing supplements with a healthcare professional is generally recommended.


Q: What is the general duration of treatment with Corentel H?

Corentel H is officially indicated for the long-term management of chronic conditions, such as high blood pressure (hypertension). As a fixed-dose combination, it is typically used on an ongoing basis to help maintain stable blood pressure levels. The specific duration of therapy is determined by the prescribing healthcare provider.


Q: Are there different strengths of Corentel H, and what are they used for?

Official regulatory documents list a range of approved tablet strengths for Corentel H, from the lowest starting dose up to the maximum labeled dose. Official guidance permits the adjustment of strength over time based on clinical need. The choice of strength is determined by the prescribing healthcare provider based on the individual patient's response and needs.


Q: Does Corentel H require any special monitoring or regular blood tests?

Regulatory documents indicate that the use of Corentel H may require regular medical monitoring. This monitoring can include checking heart rate and blood pressure, as well as blood tests to check kidney function and levels of serum electrolytes (like potassium). Regular monitoring is recommended to help ensure the safe and proper management of the therapy.


Q: How quickly can someone expect to notice the effects of Corentel H?

According to official pharmacology documents, the blood pressure-lowering effects of the individual components may begin to occur within one to two hours after taking a single dose. However, Corentel H is intended for chronic management, meaning that achieving the intended therapeutic management of blood pressure relies on continued, regular use.


Q: Can Corentel H cause weight gain or weight loss?

The safety profile in regulatory documents includes the reporting of metabolic and nutrition disorders. Although changes in weight have been reported in clinical trials or post-marketing surveillance, weight changes are not listed among the common adverse effects (ge 1%).


Q: Is Corentel H a controlled substance?

Corentel H is classified as a prescription-only medicine by regulatory authorities. Official classifications confirm that it is not designated as a controlled substance under federal or international drug schedules.


Q: Do I need a special diet while using Corentel H?

The hydrochlorothiazide component of Corentel H may alter the body's fluid and electrolyte balance, particularly the level of potassium. For this reason, official guidance notes the importance of maintaining a balanced intake of fluids and electrolytes.


Q: Are there any studies looking at Corentel H use during pregnancy?

Regulatory information addresses the use of Corentel H during pregnancy. The medicine is contraindicated (not permitted for use) specifically during the second and third trimesters. This restriction is based on studies and data indicating potential risks to the fetus.


Q: Can Corentel H affect a person’s ability to drive or operate machinery?

Official documents contain warnings that Corentel H may cause side effects such as fatigue or dizziness, especially when therapy is first started. These effects could potentially impair a person's ability to drive or safely operate complex machinery.


Q: Has Corentel H been studied in diverse ethnic populations?

The clinical studies that supported the regulatory approval of Corentel H collected and reported patient demographics, including ethnic data. Official documents and evidence summaries do not explicitly state that the drug’s effectiveness varies significantly across the different ethnic groups included in those trials.


Q: Do official documents mention a risk of dependence or addiction with Corentel H?

Official regulatory labeling for Corentel H includes a specific section covering abuse and dependence potential. According to this information, Corentel H is not associated with a risk of dependence or drug abuse.


Q: Is there a generic version of Corentel H available?

The fixed-dose combination found in Corentel H (Bisoprolol Fumarate and Hydrochlorothiazide) has approved generic formulations available in certain regions. Regulatory databases maintain public information on the status of these generic equivalents.


Q: Do studies suggest that Corentel H's effects wear off over time?

Official documents concerning the pharmacological properties of Corentel H do not report that the therapeutic effects decrease or wear off significantly over time. The approved indication anticipates sustained therapeutic management when the medicine is used continuously.


Q: What is the shelf life of Corentel H tablets?

The shelf life for Corentel H tablets is determined through stability testing and is approved by regulatory bodies. This date is printed on the original packaging. Official guidance advises against using the medicine after the expiration date has passed.


Q: Does Corentel H affect birth control pills?

The official regulatory information regarding drug interactions does not indicate a known interaction between Corentel H and oral hormonal contraceptives. Therefore, there are no specific warnings in the labeling suggesting that Corentel H would reduce the effectiveness of birth control pills.


Q: What does the patient information leaflet say about overdose with Corentel H?

The official product documents contain detailed safety information regarding potential overdose. Described effects include severe slowing of the heart rate (bradycardia), extremely low blood pressure (hypotension), and severe electrolyte imbalance. Official guidance indicates that immediate medical attention is required if an overdose is suspected.


Q: Can Corentel H cause changes in mood or personality?

The regulatory safety profile for Corentel H includes a classification for psychiatric disorders. Within this classification, official reports include mood disturbances, depression, and hallucinations. These effects are typically categorized as uncommon or rare.


Q: Is it okay to take pain relievers like ibuprofen with Corentel H?

Official labeling includes warnings regarding potential interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. These combinations may reduce the blood pressure-lowering effect of Corentel H. Furthermore, the combination may increase the risk of diminished kidney function.


Q: Does Corentel H affect fertility?

Regulatory documents include data regarding potential effects on fertility, which are often based on non-clinical studies. Studies performed in animals showed no effect on fertility. However, the clinical impact of Corentel H on human fertility is not fully established in the currently available regulatory data.


Q: What precautions should be taken when handling Corentel H?

Precautions regarding the handling and storage of Corentel H are outlined in the official product information. Regulatory documents state that handling precautions involve keeping the product in its original container, protecting it from moisture, and storing it out of the sight and reach of children and pets.


Q: Does Corentel H interact with caffeine or energy drinks?

Regulatory documents do not specifically list an interaction with caffeine or energy drinks. However, the mechanism of Corentel H is to reduce blood pressure and heart rate, effects which could potentially be opposed by substances that act as stimulants or increase blood pressure.


Q: Can Corentel H be used by people who are lactose intolerant?

The official product information, including the list of excipients (inactive ingredients), should be reviewed regarding lactose content. If the tablet contains lactose, official warnings state that the medicine should not be used by individuals who have rare hereditary problems such as total lactase deficiency or glucose-galactose malabsorption.


Q: Are there any specific warnings for individuals with a history of seizures when using Corentel H?

Official warnings related to the hydrochlorothiazide component of Corentel H advise special caution for individuals with a history of seizures. This caution is advised because severe electrolyte imbalances, which can sometimes occur with diuretic use, may potentially affect a person’s seizure threshold.


Q: What are the potential risks for someone who is breastfeeding while using Corentel H?

Regulatory documents include specific warnings regarding the use of Corentel H during lactation. It is officially noted that both active ingredients can pass into breast milk. For this reason, official guidance notes that Corentel H is generally not recommended for use during breastfeeding.


Q: Does the effectiveness of Corentel H depend on the patient's condition severity?

The clinical evidence used for the regulatory approval of Corentel H primarily involved studies in patients with mild to moderate high blood pressure. Therefore, results must be interpreted within the context of the populations examined in those regulatory trials.

How should Corentel H be stored and disposed of?

How to Store and Dispose of Corentel H

The storage and disposal instructions for Corentel H (Bisoprolol Fumarate / Hydrochlorothiazide tablets) are strictly defined by official regulatory documentation to maintain product stability.

Storage Requirements

The tablets must be stored at Controlled Room Temperature, which is maintained between 20°C and 25°C (68°F and 77°F). It is mandatory to store the medicine in its original container to protect it from moisture. To prevent accidental access, the medication must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused tablets should be discarded according to official procedures. Disposal is prioritized through a drug take-back program. If a take-back program is unavailable, the product may be disposed of in the household trash after mixing it with an unappealing substance, as directed by official guidance. The tablets must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Corentel H found in:

A-Z Index: